Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213107 | 0.88 | LMNA (0.40) | LMNAHSD17B10ALDH1A1GAAELANE | |
| SCHEMBL8612995 | 0.87 | CA2 (0.34) | ALDH1A1 | |
| SCHEMBL4532940 | 0.81 | ALDH1A1 (0.38) | ALDH1A1GAA | |
| SCHEMBL609525 | 0.81 | LMNA (0.39) | LMNAHSD17B10ALDH1A1GAAELANE | |
| Hydrochloric Acid SCHEMBL11627695 | 0.79 | LMNA (0.38) | LMNAHSD17B10ALDH1A1GAAELANE | |
| SCHEMBL2297495 | 0.78 | LMNA (0.38) | LMNAHSD17B10ALDH1A1GAA | |
| SCHEMBL441489 | 0.78 | TSHR (0.41) | LMNAHSD17B10ALDH1A1GAA | |
| SCHEMBL609524 | 0.78 | LMNA (0.40) | LMNAHSD17B10ALDH1A1GAAELANE | |
| SCHEMBL22036582 | 0.78 | FFAR3 (0.38) | LMNAHSD17B10ALDH1A1 | |
| SCHEMBL1579162 | 0.76 | GAA (0.50) | LMNAHSD17B10ALDH1A1GAAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016161067-A1 | DOUBLE-DEPROTECTED CHEMICALLY AMPLIFIED PHOTORESISTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8236821-B2 | Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8088798-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | Jensen Discovery, Inc. | 2012-01-03 | — | — | US | disclosed |
| EP-1993560-B1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2182807-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7687481-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090286758-A1 | SUBSTITUTED N-PHENYL-5-PHENYL-PYRAZOLIN-3-YL AMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-11-19 | — | — | US | disclosed |
| CN-101437398-A | Cannabinoid receptor antagonists/inverse agonists for the treatment of obesity | JENRIN DISCOVERY (US) | 2009-05-20 | — | — | CN | disclosed |
| WO-2009033125-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1993560-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007106721-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286758-A1 | SUBSTITUTED N-PHENYL-5-PHENYL-PYRAZOLIN-3-YL AMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | LMNA 2856/4885HSD17B10 2483/4885ALDH1A1 3908/4885 |
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | LMNA 4161/4885HSD17B10 1959/4885ALDH1A1 3407/4885 |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | LMNA 4161/4885HSD17B10 1959/4885ALDH1A1 3407/4885 |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | CNR2, CNR1, GPR119 | LMNA 3538/4885HSD17B10 748/4885ALDH1A1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.